Document Detail

Impact of genetic polymorphism of SDF1 3A on efficacy of captopril in Chinese patients with essential hypertension.
MedLine Citation:
PMID:  20622326     Owner:  NLM     Status:  In-Process    
OBJECTIVE: To explore the association of SDF1 3A genetic polymorphism with susceptibility of essential hypertension and captopril efficacy in patients with essential hypertension.
METHODS: A total of 214 patients with essential hypertension and 228 healthy controls were genotyped for SDF1 3A polymorphism by polymerase chain reaction-restriction fragment length polymorphism assay. Among 39 subjects with different SDF1 3A of genotypes, 13 hypertensive patients simultaneously took oral captopril (25 mg/d) and nitrendipine (30 mg/d), and 12 patients orally received nitrendipine alone for 8 consecutive weeks, and 14 healthy controls did not take any agents. The blood pressure of all subjects was measured to evaluate the therapeutic efficacy.
RESULTS: There was a significant difference in the plasma SDF-1 level in individuals with AA+AG genotypes or GG genotypes of SDF1 3A treated with nitrendipine plus captopril compared with healthy control (P < 0.05). Carriers with AA genotypes of SDF1 3A had lower total protein and globulin than those with GG genotypes (P < 0.05). After captopril treatment, hypertensive patients with AA+AG genotypes had bigger attenuated systolic blood pressure compared with those with GG genotypes (P < 0.05).
CONCLUSION: Genetic polymorphism of SDF1 3A could influence the therapeutic efficacy of captopril in Chinese hypertensive patients.
Yan Yan; Chen Ning; Huan Zhou; Xiheng Yang; Tianlun Yang; Zhaoqian Liu
Related Documents :
17198546 - Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact...
17372766 - An investigation of genome-wide associations of hypertension with microsatellite marker...
7875756 - Association of the alpha-adducin locus with essential hypertension.
17635856 - Genome-wide scans meta-analysis for pulse pressure.
12517246 - Clinical use of nifedipine gits in the treatment of hypertension: an overview.
20436036 - Cardiac resynchronization therapy for the causal treatment of heart failure with preser...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences     Volume:  35     ISSN:  1672-7347     ISO Abbreviation:  Zhong Nan Da Xue Xue Bao Yi Xue Ban     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-07-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101230586     Medline TA:  Zhong Nan Da Xue Xue Bao Yi Xue Ban     Country:  China    
Other Details:
Languages:  eng     Pagination:  549-56     Citation Subset:  IM    
Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inhibition of HBV-DNA replication and expression by siRNA based on magnetic nanoparticles transferin...
Next Document:  Effect of autophagy on paclitaxel-induced CaSki cell death.